Home
About Us¡¡|¡¡Market Research¡¡|¡¡Research Report¡¡|¡¡Report Store¡¡|¡¡International Trade¡¡|¡¡Strategic Investment¡¡|¡¡Contact Us
Report Store

Published Date: May 20 2013
Page Count: 118
Unit Price: US$ 750
Site License: US$3500
global Site License:US$5250
Format: Electronic PDF copy
Publisher: Access China Management Consulting Ltd




China Pharmaceutical Guidebook Series (4) (2013 edition)
Material and Clinical Trial Requirements of Application and Approval for Imported Drug Registration:
A Guidebook of Registration Application for Imported Traditional Chinese Medicines and Natural Medicines
Summary Table of contents

China possesses a fourth population in the world and has one of the largest drug markets round the world. By 2012, sales on the Chinese drug market have reached RMB 926.1billion (about US$147 billion) reported by the «2012:  Report of China Pharmaceutical Market» published by Chinese Academy of Social Sciences. It is estimated that it will exceed RMB 1,000 billion by 2013. A series of factors, such as an increasingly ageing population, accelerating growth of urban population as well as expansion of healthcare covering urban and rural, will grow the Chinese drug market with a growth rate over 20 percent per annum in next three years. China is expected to become the second largest drug market in the world by 2015.

 

Since the reform and open door policy implemented by Chinese authorities in the late 1970s, the door of the Chinese drug market began opening up to the world step by step, which gave a fillip to the imported drugs from overseas pharmaceutical manufacturers and producers. By 2012, sales of imported drugs have shared one fourth on the Chinese drug market. As China joins the World Trade Organization (WTO) and integrates more completely into the global economy, it will further open the door of a lucrative drug market for overseas pharmaceutical companies. More and more overseas pharmaceutical manufacturers and producers expect to enter such drug market and seize a larger part of such drug market. To enter such a lucrative drug market, the first obstacle faced by overseas pharmaceutical manufacturers and producers is how to file the application for their imported drug registration with Chinese pharmaceutical authorities. In China, the process of application and approval for imported drug registration is very complex, because the Chinese pharmaceutical authorities administer and control this process by exorbitant administrative measures and regulations, moreover, these exorbitant administrative regulations are variable and lack of transparency. Therefore, a comprehensive and thorough knowledge of the latest Chinese regulations for imported drug registration has been become an essential prerequisite for overseas pharmaceutical manufacturers and producers to achieve a successful application for their products entry into the Chinese drug market. In despite of since the drug registration implemented by the Chinese pharmaceutical authorities on December 1, 2002, its regulatory regime has experienced countless changes, and become increasingly compatible with international standards, in turn, its ongoing consolidation will eventually contribute to a healthier market environment. The Chinese Pharmaceutical authority promulgated the last ¡°Measures for the Administration of Drug Registration¡± on July 10 2007, and the last ¡°Measures¡± entered into force since October 1, 2007. However, the practical operations for application and approval of imported drug registration have been constantly changed, because the amendment of ¡°Measures¡± is delayed. Under such circumstance, Access China Management Consulting Ltd published the China Pharmaceutical Guidebook Series: 2013 Edition. The aim of this guidebook series is to guide overseas pharmaceutical manufacturers and producers to achieve a successful application and approval for their imported drug registration. This guidebook series are composed of four guidebooks as the following.

 

l        Latest Chinese Regulations for Imported Drug Registration: 2013 Edition

A Comprehensive Guidebook for Foreign Pharmaceutical Companies

 

l        Material and Clinical Trial Requirements of Application and Approval for Imported Drug Registration: 2013 Edition

A Guidebook for Application of Imported Chemical Drugs Registration

 

l        Material and Clinical Trial Requirements of Application and Approval for Imported Drug Registration: 2013 Edition

A Guidebook for Application of Imported Biological Product Registration

 

l        Material and Clinical Trial Requirements of Application and Approval for Imported Drug Registration: 2013 Edition

A Guidebook for Application of Imported Traditional Chinese Medicine and Natural Medicine Registration

 

The traditional medicines in Orient, especially, the traditional Chinese medicines are always regarded by occidental as mysterious medicines. Until today not only the chemical composition of traditional Chinese medicines almost can not been expressed by a precise chemical structural formula, but also the indications of the majority of traditional Chinese medicines still can not been clearly described by the modern medical terminologies. How the Chinese drug authorities to administer the registration application for such mysterious traditional Chinese medicines? This is the fourth guidebook of the China Pharmaceutical Guidebook Series. It will provide a detailed introduction of the Chinese pharmaceutical authorities¡¯ requirements for materials and clinical trials of application and approval for imported traditional Chinese medicine. The Chinese pharmaceutical authorities collect the traditional Chinese medicines and the natural medicines into a category for registration application. Therefore, this guidebook will provide not only the introduction for registration application of imported traditional Chinese medicines but for the natural medicines.

 

In China, like in other Western countries, the pharmaceutical authority ----- China Food and Drug Administration (hereafter called CFDA) requests applicant to submit complicate and reliable materials for application of medicine registration. The CFDA stipulated the classification of medicine registration in order to administer the application of traditional Chinese medicine and natural medicine registration. At the same time, the CFDA collected the materials for application of traditional Chinese medicine and natural medicine registration into four categories and 33 items in accordance with various medicine categories. When an application of traditional Chinese medicine and natural medicine registration is filed, the CFDA will request applicant to not only submit designated material items in accordance with prescribed category of traditional Chinese medicines and natural medicines to apply for registration, but also conduct the clinical trials for certain categorical traditional Chinese medicines and natural medicines.

 

Report Highlights

l        An overview of the classification of medicine registration formulated by the CFDA (China Food and Drug Administration in China).

l        The material items for application of medicine Registration.

l        The requirements of material items for application of medicine registration.

l        The requirements of clinical trial for application of medicine registration.

l        The significant suggestions for overseas pharmaceutical manufacturers and producers looking to achieve a successful application for their traditional Chinese medicine and natural medicine registration in China.

l        Many useful resources of law and regulations, including the Drug Administration Law of the People¡¯s Republic of China, the Regulations for Implementation of the Drug Administration Law of the People¡¯s Republic of China, the Chinese Good Clinical Practice of Pharmaceutical Products, the Form of Registration Application for Imported Drug, and so on.

 

  Who should buy this report?

  • Companies wishing to enter a lucrative drug market in China.
  • Companies interested in understanding the latest Chinese regulations on application and approval for imported drug registration.
  • Senior executive officers engaging regulatory and registration affairs for drugs.

 

Need more information?
Call us or email us!
Tel:(86)25-85337409
E-mail:zengxian.wu@gmail.com
Home
About Us
Market Research
Research Report
Report Store
International Trade
Strategic Investment
Contact Us
Copyright © 2007-2017 Access China. All rights reserved.   ËÕICP±¸12078369ºÅ-1   Privacy / Terms and conditions